Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia
NCT02100839Phase 2Completed
- Sponsor
- LipimetiX Development, Inc.
- Start
- Mar 2014
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AEM-28 in hypercholesterolemia (2 arms), sponsored by LipimetiX Development, Inc. Primary endpoints: Number of Participants Who Incurred at Least One Treatment Emergent Event, Number of Participants Who Incurred Mild Treatment Emergent Adverse Events and 1 more. Started Mar 2014; status: completed.
02
Drugs
AEM-28
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02100839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100839.